BR112018072887A2 - método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto - Google Patents
método de tratamento de câncer de cérebro em um indivíduo, e utilização de um compostoInfo
- Publication number
- BR112018072887A2 BR112018072887A2 BR112018072887-0A BR112018072887A BR112018072887A2 BR 112018072887 A2 BR112018072887 A2 BR 112018072887A2 BR 112018072887 A BR112018072887 A BR 112018072887A BR 112018072887 A2 BR112018072887 A2 BR 112018072887A2
- Authority
- BR
- Brazil
- Prior art keywords
- brain cancer
- individual
- compound
- treatment method
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
são divulgados métodos de utilização de derivados de 2-anilinopirimidina substituída e sais, solvatos ou composições farmaceuticamente aceitáveis, para o tratamento de câncer de cérebro, em particular câncer de cérebro metastático mediado por egfr.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662334830P | 2016-05-11 | 2016-05-11 | |
US62/334,830 | 2016-05-11 | ||
PCT/US2017/032066 WO2017197062A1 (en) | 2016-05-11 | 2017-05-11 | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018072887A2 true BR112018072887A2 (pt) | 2019-03-06 |
Family
ID=60267544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018072887-0A BR112018072887A2 (pt) | 2016-05-11 | 2017-05-11 | método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto |
Country Status (17)
Country | Link |
---|---|
US (1) | US11052086B2 (pt) |
EP (1) | EP3454860A4 (pt) |
JP (1) | JP6908287B2 (pt) |
KR (1) | KR20190006991A (pt) |
CN (1) | CN109715164A (pt) |
AU (1) | AU2017264839B2 (pt) |
BR (1) | BR112018072887A2 (pt) |
CA (1) | CA3023228A1 (pt) |
CO (1) | CO2018012061A2 (pt) |
EA (1) | EA201892311A1 (pt) |
IL (1) | IL262801A (pt) |
MX (1) | MX2018013602A (pt) |
PH (1) | PH12018502360A1 (pt) |
SG (1) | SG11201809931YA (pt) |
TW (1) | TW201740951A (pt) |
WO (1) | WO2017197062A1 (pt) |
ZA (1) | ZA201807353B (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3399968B8 (en) | 2016-01-07 | 2021-12-01 | Xuanzhu Biopharmaceutical Co., Ltd. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
SG11201810976TA (en) | 2016-06-17 | 2019-01-30 | Beta Pharma Inc | Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof |
MX2019015177A (es) | 2017-06-16 | 2020-02-07 | Beta Pharma Inc | Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas. |
CN111100117B (zh) * | 2019-12-18 | 2021-02-19 | 上海倍而达药业有限公司 | 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078409B2 (en) * | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
CA2683804A1 (en) * | 2007-04-13 | 2008-10-23 | Dana Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
TWI619713B (zh) * | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
AU2012250517B2 (en) * | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
PL3686194T3 (pl) * | 2011-07-27 | 2022-01-17 | Astrazeneca Ab | Związki 2-(2,4,5-podstawione-anilino)pirymidynowe |
US20150018369A1 (en) * | 2012-01-09 | 2015-01-15 | University Of Washington Through Its Center For Commercialization | Compositions and Methods for Treating Malignant Astrocytomas |
BR112016029662B1 (pt) | 2014-06-19 | 2023-10-24 | Takeda Pharmaceutical Company Limited | COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO |
CN106458969A (zh) * | 2014-08-25 | 2017-02-22 | 四川海思科制药有限公司 | 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途 |
CN105461695B (zh) | 2014-09-29 | 2018-03-27 | 齐鲁制药有限公司 | 嘧啶或三嗪衍生物及其制备方法和用途 |
CN105085489B (zh) * | 2014-11-05 | 2019-03-01 | 益方生物科技(上海)有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
AU2015360360B2 (en) | 2014-12-11 | 2020-06-25 | Beta Pharma (Shanghai) Co., Ltd. | Substituted 2-anilinopyrimidine derivatives as EGFR modulators |
-
2017
- 2017-05-11 CA CA3023228A patent/CA3023228A1/en not_active Abandoned
- 2017-05-11 MX MX2018013602A patent/MX2018013602A/es unknown
- 2017-05-11 AU AU2017264839A patent/AU2017264839B2/en active Active
- 2017-05-11 TW TW106115602A patent/TW201740951A/zh unknown
- 2017-05-11 EP EP17796819.5A patent/EP3454860A4/en active Pending
- 2017-05-11 CN CN201780036188.7A patent/CN109715164A/zh active Pending
- 2017-05-11 KR KR1020187035380A patent/KR20190006991A/ko not_active Application Discontinuation
- 2017-05-11 EA EA201892311A patent/EA201892311A1/ru unknown
- 2017-05-11 SG SG11201809931YA patent/SG11201809931YA/en unknown
- 2017-05-11 JP JP2018559217A patent/JP6908287B2/ja active Active
- 2017-05-11 WO PCT/US2017/032066 patent/WO2017197062A1/en unknown
- 2017-05-11 US US16/300,949 patent/US11052086B2/en active Active
- 2017-05-11 BR BR112018072887-0A patent/BR112018072887A2/pt not_active Application Discontinuation
-
2018
- 2018-11-02 ZA ZA2018/07353A patent/ZA201807353B/en unknown
- 2018-11-05 IL IL262801A patent/IL262801A/en unknown
- 2018-11-07 CO CONC2018/0012061A patent/CO2018012061A2/es unknown
- 2018-11-09 PH PH12018502360A patent/PH12018502360A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201807353B (en) | 2019-08-28 |
AU2017264839B2 (en) | 2021-08-05 |
JP2019514996A (ja) | 2019-06-06 |
US20190365755A1 (en) | 2019-12-05 |
CO2018012061A2 (es) | 2018-11-22 |
TW201740951A (zh) | 2017-12-01 |
EA201892311A1 (ru) | 2019-06-28 |
SG11201809931YA (en) | 2018-12-28 |
WO2017197062A1 (en) | 2017-11-16 |
EP3454860A4 (en) | 2020-01-15 |
CA3023228A1 (en) | 2017-11-16 |
KR20190006991A (ko) | 2019-01-21 |
PH12018502360A1 (en) | 2019-03-25 |
MX2018013602A (es) | 2019-08-22 |
AU2017264839A1 (en) | 2018-11-22 |
CN109715164A (zh) | 2019-05-03 |
US11052086B2 (en) | 2021-07-06 |
IL262801A (en) | 2018-12-31 |
JP6908287B2 (ja) | 2021-07-21 |
EP3454860A1 (en) | 2019-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
EP3399982A4 (en) | ANTI-EGFR ASSOCIATIONS FOR THE TREATMENT OF TUMORS | |
IL253979A0 (en) | Methods, preparations and kits for cancer treatment | |
GB2541571A (en) | Pharmaceutical compositions | |
MX2021007773A (es) | Compuestos inhibidores de egfr. | |
EA201692472A1 (ru) | Соединения для лечения рака мозга | |
MX2015011606A (es) | Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer. | |
BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
BR112018072887A2 (pt) | método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto | |
CY1123592T1 (el) | Αναστολεας κινασης aurora a | |
MX2018010993A (es) | Derivados de icariina e icaritina. | |
AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
MY186475A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
MX2018001369A (es) | Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos. | |
CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
IL268163A (en) | Methods, compositions, and kits for treatment of cancer | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
BR112017009854A2 (pt) | composto, uso de um composto, e, método para tratamento de leucemia. | |
EA201691896A1 (ru) | Соединения и способы их применения | |
IL288953A (en) | Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors | |
WO2018081817A3 (en) | Targeting microrna-101-3p in cancer therapy | |
HK1251476A1 (zh) | 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |